Quickstart Highlights
CJC-1295 DAC (5 mg Vial) & Ipamorelin (5 mg Vial) dosage protocol combines two research peptides frequently studied together for their synergistic effects on growth hormone (GH) release.
- CJC-1295 DAC ~1–2 mg per week (once or twice weekly)
- Ipamorelin ~300–500 mcg per day (1–2 daily injections for standard use)
- Common cycle length is 4–8 weeks, based on research requirements
- Reconstitute each vial with bacteriostatic water (up to 3 mL per vial)
- Keep reconstituted vials refrigerated (2–8°C) and use within 14–28 days
Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
CJC-1295 DAC (5 mg Vial): Standard / Gradual Approach
Reconstitute with 2 mL of bacteriostatic water to achieve a concentration of 2.5 mg/mL. Each full vial = 5 mg total. This approach typically allows for ~1–2 mg total weekly.
| Week | Weekly Total (mg) | Per Injection (mg) | Units (mL) | Frequency |
|---|---|---|---|---|
| Weeks 1–4 | 1–2 mg/week | 0.5–1 mg | ~0.2–0.4 mL (20–40 units) | 1–2× per week |
For example, if you plan on using 2 mg per week in 2 injections: each injection is ~1 mg (0.4 mL or ~40 units). Lower weekly totals (1 mg/week) might require just one injection of 0.4 mL.
- Draw 2.0 mL of bacteriostatic water into a sterile syringe.
- Inject slowly along the vial wall to minimize foam.
- Gently swirl the vial—avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
CJC-1295 DAC (5 mg Vial): Advanced / Aggressive Approach
Reconstitute with 1 mL of bacteriostatic water to achieve a higher concentration of 5 mg/mL. Typically used if aiming for ~3 mg/week (divided doses) in performance-focused research.
| Week | Weekly Total (mg) | Per Injection (mg) | Units (mL) | Frequency |
|---|---|---|---|---|
| Weeks 1–4 | 3 mg/week | ~1 mg | ~0.2 mL (20 units) | 3× per week |
If dosing at 3 mg/week in 3 separate injections, each injection is ~1 mg (~20 units) for easy measurement. Higher reconstitution concentration means a smaller volume per injection.
- Draw 1.0 mL of bacteriostatic water.
- Inject slowly along the vial wall.
- Gently swirl—avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Ipamorelin (5 mg Vial): Standard / Gradual Approach
Reconstitute with 3 mL of bacteriostatic water for a concentration of ~1.67 mg/mL (1670 mcg/mL). This accommodates moderate daily injections in the 300–500 mcg range.
| Week | Daily Total (mcg) | Per Injection (mcg) | Units (mL) | Frequency |
|---|---|---|---|---|
| Weeks 1–4 | 300–500 mcg/day | 300–500 mcg |
~0.18–0.3 mL (18–30 units)
per injection |
1× daily |
For instance, a 500 mcg single daily dose is ~0.3 mL (~30 units). If you opt for smaller, multiple daily doses (e.g., 2× 250 mcg), each injection is ~0.15 mL (~15 units).
- Draw 3.0 mL of bacteriostatic water.
- Inject it slowly along the vial wall.
- Gently swirl until dissolved; avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
- If your daily injection volume falls below ~10 units, consider using a smaller (50-unit) syringe for better precision.
Ipamorelin (5 mg Vial): Advanced / Aggressive Approach
Reconstitute with 1 mL of bacteriostatic water to obtain 5 mg/mL (5000 mcg/mL). Suited for higher-dosage protocols (e.g., 600–700 mcg daily) often split into 2–3 doses.
| Week | Daily Total (mcg) | Per Injection (mcg) | Units (mL) | Frequency |
|---|---|---|---|---|
| Weeks 1–4 | 600–700 mcg/day | ~300–350 mcg | ~0.06–0.07 mL (6–7 units) | 2× daily |
At 5 mg/mL, even moderate doses result in very small volumes.
Example: 300 mcg = 0.06 mL (~6 units). If measuring below 10 units, consider using a 50-unit or 30-unit syringe for accuracy.
- Draw 1.0 mL of bacteriostatic water.
- Inject slowly; swirl gently until dissolved.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Combining CJC-1295 DAC & Ipamorelin in a Stack
Many researchers combine these two peptides for potentially enhanced GH release. Dosage examples:
- CJC-1295 DAC: 1–2 mg per week (1–2 injections), or up to ~3 mg/week in advanced protocols
- Ipamorelin: 300–700 mcg per day, split into 1–3 daily injections
- Reconstitute each peptide in its own vial; do not combine into the same syringe
For best accuracy, keep each injection volume between ~10–60 units whenever possible by adjusting reconstitution volumes.
Supplies Needed
Basic materials for a typical 4–8 week research cycle.
- Peptide Vials:
- CJC-1295 DAC (5 mg Vial) – Product ID: 13371
- Ipamorelin (5 mg Vial) – Product ID: 1042 (Adjust total vials based on dosage and cycle length)
- Insulin Syringes: 1 per injection (30–100 unit size)
- Bacteriostatic Water: 1× 30 ml or as needed
- Alcohol Swabs: 1 box
![Peptide Vial](http://www.dosagepeptide.com/wp-content/uploads/2025/12/Generic-Stack-Vial-scaled.png" alt="CJC-1295 DAC (5 mg Vial) & Ipamorelin (5 mg Vial)" /></div>)
Protocol Overview
A concise approach for stacking CJC-1295 DAC and Ipamorelin in short-to-moderate research cycles.
- Goal: Enhanced GH release, potential synergy in injury repair or performance
- CJC-1295 DAC: 1–3 mg weekly (1–3 injections)
- Ipamorelin: ~300–700 mcg daily, split if necessary
- Cycle Length: 4–8 weeks; re-assess as needed
- Reconstitution: Up to 3 mL total to maintain practical syringe units
Dosing Protocol
Recommended scheduling framework for combining these peptides effectively.
- Injection Method: Subcutaneous or intramuscular (rotate sites)
- CJC-1295 DAC Schedule: Once or twice weekly (standard) or up to 3× weekly (advanced)
- Ipamorelin Schedule: 1–3 daily injections, as research dictates
- Timing: No strict timing requirement between the two; use separate syringes
- Duration: Typical 4–8 weeks; some extend to 12 weeks with periodic breaks
Storage Instructions
Proper handling preserves peptide quality.
- Lyophilized: Store at 2–8°C until ready to mix
- Reconstituted: Refrigerate at 2–8°C; use within 14–28 days
- Protect from light; keep vials upright if possible
- Avoid repeated freeze-thaw cycles
Important Notes
Tips for safe, consistent research usage.
- Use new, sterile insulin syringes for each injection; rotate injection sites.
- Maintain consistent protocol; peptides often show best outcomes with regular dosing.
- Monitor for adverse reactions; consult a professional if concerns arise.
- Never mix CJC-1295 DAC and Ipamorelin in the same syringe; reconstitute each in its own vial.
How This Works
CJC-1295 DAC and Ipamorelin both target the growth hormone (GH) axis, but via different mechanisms.
- CJC-1295 DAC: A long-acting GHRH analog that extends GH release and increases IGF-1 levels over time.
- Ipamorelin: A selective GH secretagogue known for triggering GH release without significantly affecting cortisol or prolactin.
- Stacking can provide a more sustained GH pulse (from CJC-1295) plus consistent GH peaks (from Ipamorelin).
Potential Benefits & Side Effects
Research explores various benefits, with some caution for side effects.
- Possible support for muscle repair, injury recovery, and collagen synthesis
- Increased GH and IGF-1 can lead to improved tissue repair in certain models
- Potential mild side effects: injection-site irritation, water retention, headaches
- Long-term safety and efficacy continue to be investigated
Injection Technique
Complementary habits can influence peptide research outcomes.
- Maintain a balanced diet with adequate protein intake
- Engage in regular exercise; allow proper rest and recovery
- Prioritize sleep and stress management
Lifestyle Factors
Complementary strategies for best outcomes.
- Maintain a protein-rich diet and stay hydrated
- Engage in regular exercise; allow adequate rest
- Manage stress and prioritize quality sleep
Recommended Source
We recommend Prime Lab Peptides for high-purity CJC-1295 DAC & Ipamorelin.
Why Prime Lab Peptides?
- Verifies ≥99% purity through independent lab testing
- Trusted by researchers seeking reliable results
- Follows rigorous manufacturing standards for consistent quality
Important Note
This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.
References
References
-
Journal of Clinical Endocrinology & Metabolism
— Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults -
European Journal of Endocrinology
— Ipamorelin, the first selective growth hormone secretagogue -
Endocrine Reviews
— Growth hormone secretagogues: mechanisms and clinical applications -
Sleep Medicine Reviews
— Sleep and the GH/IGF-1 axis: physiological and clinical implications -
Bachem
— Handling and storage guidelines for peptides (lyophilized stability) -
Bachem
— Reconstituted peptide storage and stability recommendations -
Translational Andrology and Urology (PMC)
— GH secretagogues in body composition management for hypogonadal males -
International Journal of Surgery (PubMed)
— Ipamorelin for postoperative ileus: tolerability and safety in bowel resection patients -
NCBI Bookshelf
— Parenteral medication administration: subcutaneous injection technique -
CDC
— Vaccine administration guidelines: subcutaneous route (no aspiration required) -
Growth Hormone & IGF Research (ScienceDirect)
— Ipamorelin induces longitudinal bone growth in rats -
Physiological Reviews
— The somatotropic axis: GH and IGF-1 regulation and actions -
Clinical Drug Investigation (PMC)
— Subcutaneous drug delivery: pharmacokinetic considerations -
Pure Lab Peptides
— CJC-1295 DAC (5 mg) product page -
Pure Lab Peptides
— Ipamorelin (5 mg) product page